{"filings":[{"id":2411683,"accession_number":"0001213900-26-092657","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2026-08-21T21:00:13+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq bid price deficiency notice for ESLA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified on Aug 17, 2026 that ESLA bid price stayed below $1.00 for 30 straight days (Jul 6–Aug 14).","Company has until Feb 16, 2027 (180-day period) to regain compliance via 10 consecutive days at $1.00+.","Reverse stock split, if used, must be completed by at least 10 business days before compliance deadline.","If not cured, possible second 180-day extension or delisting appeal; no immediate impact on listing/trading.","Management evaluating options to regain bid price compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1363156,"accession_number":"0001213900-26-073847","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2026-06-30T21:29:37+00:00","items":["5.07"],"status":"ready","headline":"Estrella Immunopharma stockholders ratify auditor at 2025/2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ratified Macias Gini & O'Connell LLP as independent auditor for fiscal year ending Dec 31, 2026.","Votes: 30,351,203 for, 400 against, 5 abstain; no broker non-votes.","Annual meeting held June 29, 2026; quorum of ~70.5% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109792,"accession_number":"0001213900-26-003998","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq deficiency notice for failure to hold annual meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 7, 2026, citing non-compliance with Listing Rule 5620(a) for not holding annual meeting.","Company has 45 calendar days to submit a plan to regain compliance.","Expects to convene annual meeting in April 2026 and will consult with Nasdaq on compliance.","No immediate impact on listing or trading of ESLA common stock or ESLAW warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109791,"accession_number":"0001213900-26-001777","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Estrella Immunopharma raises $8.0M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8.0M from sale of 4,063,290 shares, 1,000,000 pre-funded warrants, and 7,594,935 PIPE common warrants.","Combined unit price of $1.58 per share/warrant; PIPE warrants exercisable at $1.39 for 5 years.","Net proceeds for general corporate purposes and working capital to advance Phase II trial of EB103.","Placement agent Aegis Capital Corp. received a 6% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126329,"accession_number":"0001213900-25-118097","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).","High-dose cohort achieved 100% complete response (CR) rate at Month 1 in evaluable patients.","Phase II expansion will evaluate EB103 in relapsed/refractory B-cell NHL at RP2D.","Majority of Phase I patients were high-risk, including one with CNS lymphoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126328,"accession_number":"0001213900-25-107249","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.","All patients are high-risk, including one with CNS lymphoma; no treatment-related serious adverse events reported.","DSMB will review cumulative data to determine Recommended Phase II Dose (RP2D) for expansion phase.","EB103 is a CD19-redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143082,"accession_number":"0001213900-25-093197","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Estrella Immunopharma regains Nasdaq compliance on bid price and market value","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq minimum bid price rule (5550(a)(2)) after 10 consecutive days of closing bid ≥ $1.00 (Sept 9-22, 2025).","Regained compliance with Nasdaq minimum market value of listed securities rule (5550(b)(2)) after 17 consecutive days of MV ≥ $35M (Aug 28-Sept 22, 2025).","Both compliance matters are now closed; previously disclosed non-compliance resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143081,"accession_number":"0001213900-25-092471","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Estrella Immunopharma appoints Jia Dengyao to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Board appointed Jia Dengyao as director effective September 22, 2025.","Mr. Jia has not been named to any Board committees as of the filing.","Company entered into standard indemnification agreement with new director.","Appointment adds a new independent voice but no other details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143080,"accession_number":"0001213900-25-072746","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq non-compliance notice for MVLS below $35M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 1, 2025 for failing to maintain minimum MVLS of $35M for 30 consecutive business days.","Non-compliance period identified as June 13, 2025 to July 31, 2025.","Company has 180 days, until Jan 28, 2026, to regain compliance with MVLS of $35M+ for 10 consecutive business days.","Also noted non-compliance with alternative listing rules 5550(b)(1) and 5550(b)(3).","No immediate effect on listing; Company will monitor and consider options but cannot assure regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161191,"accession_number":"0001213900-25-051361","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma activates second clinical site for Phase I/II STARLIGHT-1 NHL trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Baylor Research Institute in Dallas, TX now open for patient enrollment in STARLIGHT-1 trial.","Trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell NHL.","Open-label, dose escalation/expansion Phase I/II study to determine Recommended Phase II Dose in adults ≥18.","CEO Cheng Liu states partnership will accelerate development and increase patient access to EB103."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161190,"accession_number":"0001213900-25-050329","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).","Net proceeds to fund Phase I STARLIGHT-1 trial of EB103 CD19-targeted T-cell therapy in NHL.","True-Up provision: additional shares if 12-month closing price below $1.50 (floor $0.20).","Company agreed to file resale registration statement for shares issued in PIPE.","Closing subject to customary conditions; investor support cited as confidence in ARTEMIS platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161189,"accession_number":"0001213900-25-048597","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma doses first patient in STARLIGHT-1 second cohort for EB103 in NHL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in second cohort of Phase I/II STARLIGHT-1 trial evaluating EB103 at higher dose.","No dose-limiting toxicities or treatment-related serious adverse events observed in first cohort.","Complete response reported in first cohort; trial targets advanced B-cell non-Hodgkin's lymphomas.","CEO Cheng Liu highlights potential for HIV-associated and CNS lymphoma patients currently excluded from CAR-T."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161188,"accession_number":"0001213900-25-039261","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq bid price deficiency notice; faces potential delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Estrella that common stock failed to maintain $1.00 minimum bid for 30 consecutive days through April 28, 2025.","Company has 180-day compliance period (until October 27, 2025) to regain compliance with Bid Price Rule.","If not compliant by October 27, may seek additional 180-day period if it meets other listing standards.","No immediate effect on listing; common stock and warrants continue trading on Nasdaq under ESLA and ESLAW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179351,"accession_number":"0001213900-25-015851","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.","DSMB approved escalation to second cohort at 5 million receptor-positive T cells/kg of EB103 therapy.","Preliminary data showed tumor responses in all patients at Month 1; favorable safety profile.","STARLIGHT-1 is an open-label, multi-center 3+3 dose-escalation study to determine RP2D for EB103."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179350,"accession_number":"0001213900-25-015364","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma receives Buy rating from D. Boral Capital with $16 price target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["D. Boral Capital initiates coverage on Estrella (ESLA) with a Buy rating and 12-month price target of $16.00 per share.","Lead candidate EB103, a CD19/CD22-targeted ARTEMIS® T-cell therapy, is in Phase I/II trials for B-cell Non-Hodgkin's Lymphoma.","D. Boral Capital's valuation model assumes 30% probability of success and a 30% discount rate.","D. Boral Capital will also provide investment banking services, creating a potential conflict of interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196049,"accession_number":"0001213900-24-109285","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Estrella Immunopharma regains compliance with both Nasdaq listing requirements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Stockholders' Equity Requirement after market value of listed securities exceeded $35M for 10 consecutive days ending Dec 10, 2024.","Regained compliance with Minimum Bid Price Requirement after closing bid price of common stock stayed at $1.00+ for 10 consecutive days ending Dec 10, 2024.","Both Nasdaq deficiency matters are now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196048,"accession_number":"0001213900-24-106238","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Estrella Immunopharma extends equity line with White Lion to Dec 2025, adds rapid share purchase mechanism","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment extends existing up-to-$50M stock purchase agreement from Dec 30, 2024 to Dec 30, 2025.","New 'Rapid Purchase' mechanism allows expedited share sales at lowest traded price on notice date.","Rapid purchase limit is the lesser of 20% of average daily trading volume or investment limit divided by highest close over five days.","Standard purchase discount remains 97% (up to $25M) then 98%; rapid purchases use lowest traded price (0% discount).","Company delivers Rapid Purchase Notice by 11:00 a.m. NY time with concurrent DWAC transfer; payment due next business day by 5 p.m."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196047,"accession_number":"0001213900-24-102899","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Estrella Immunopharma changes fiscal year end to Dec 31, transition period Jul-Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved fiscal year change from June 30 to December 31 effective November 25, 2024.","Transition period covers July 1, 2024 through December 31, 2024.","Company will file Form 10-KT with audited financials for the transition period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196046,"accession_number":"0001213900-24-102134","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.","Has until Jan 3, 2025 to submit a compliance plan; Nasdaq may grant up to 180-day extension.","Separate bid price deficiency: common stock below $1.00 for 30 consecutive business days; cure period until May 19, 2025.","Both deficiencies have no immediate effect on listing, but failure to regain compliance could lead to delisting.","Company evaluating options to regain compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196045,"accession_number":"0001213900-24-095506","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Estrella Immunopharma enters employment agreement with CEO Cheng Liu; base salary $250,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary of $250,000 per year, plus annual cash bonus based on performance metrics set by Compensation Committee.","Severance: 6 months base salary for termination without cause or resignation for good reason; 12 months plus equity acceleration if tied to change in control.","Agreement includes non-disclosure and confidentiality covenants; effective November 1, 2024, at-will employment.","CEO retains ability to hold outside directorships and positions, subject to Board review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196044,"accession_number":"0001213900-24-095507","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K/A","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Estrella Immunopharma enters consulting agreement with chairperson's company Cofame","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estrella Immunopharma entered a Consulting Agreement with Cofame Investment Management, owned by Chairperson Hong Zhang, for advisory services up to three days per week.","Cofame receives $55,000 upfront and an annual fee of $220,000; Hong Zhang granted option to purchase 1,000,000 shares under the 2023 Omnibus Incentive Plan.","Option vests 25% on August 1, 2025, with the remaining 75% vesting monthly over 36 months, contingent on continued service.","The Audit Committee reviewed and approved the agreement as a related-party transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212294,"accession_number":"0001213900-24-071174","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Estrella Immunopharma appoints Hong Zhang as Chairperson and Board member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hong Zhang appointed Chairperson and director effective Aug 14, 2024; board expands from 5 to 6.","Ms. Zhang brings 25+ years financial and corporate strategy experience; previous Chairman Dr. Cheng Liu remains on board.","Compensation: $5,000/quarter as director + $2,500/quarter as Chairperson; expenses reimbursed.","Company also negotiating consulting agreement with entity owned by Ms. Zhang for Asian strategic initiatives; terms pending approval.","Press release notes dosing of first patient in Phase I/II trial STARLIGHT-1 for EB103 in R/R B-cell NHL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212293,"accession_number":"0001213900-24-065292","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.","Target indication: relapsed/refractory B-cell Non-Hodgkin's Lymphomas (R/R B-cell NHL).","Trial is open-label, dose escalation/expansion to assess safety and determine Recommended Phase II Dose (RP2D).","Principal Investigator: Naseem Esteghamat, M.D., at UC Davis Comprehensive Cancer Center.","Clinical trial identifier on ClinicalTrials.gov: NCT06343311."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212292,"accession_number":"0001213900-24-058085","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma merges wholly-owned sub Estrella Biopharma into parent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger effective June 30, 2024; Estrella Biopharma ceased to exist, Estrella Immunopharma survives.","No changes to management, board, ownership, charter, or bylaws as a result of the merger.","Merger approved by unanimous written consent of board; intended to simplify corporate structure and streamline financial reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231229,"accession_number":"0001213900-24-042444","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Estrella Immunopharma amends clinical trial service agreement with Eureka to clarify termination payment terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to SOW #001 for EB103 anti-CD19 ARTEMIS® clinical trial clarifies pay-on-termination obligations.","Upon termination, Estrella pays only for achieved milestones, pass-through costs, and third-party commitments before notice.","Eureka must use commercially reasonable efforts to cancel or reduce such third-party commitments.","Amendment effective March 4, 2024; filed on May 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231228,"accession_number":"0001213900-24-031716","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.","IIS study: 6/12 CR (50%), 4/12 PR (33%), ORR 83%; no severe CRS; durable responses up to 23.2 months.","Partnered with Imugene (ASX:IMU) to combine CF33-CD19t oncolytic virus with EB103 for solid tumors.","Pipeline includes EB104 (CD19/CD22 dual-targeting) for lymphoma and EB201 for SLE (preclinical)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249624,"accession_number":"0001213900-24-021186","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma details $1M share repurchase: open market buys via 10b5-1 plan over 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $1,000,000 in common stock repurchases (first announced Jan 30, 2024).","Repurchases expected via open market trades at prevailing prices under a Rule 10b5-1 plan.","Company will use existing cash reserves; plan may be modified or terminated based on market conditions.","Expected to occur within the next 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249623,"accession_number":"0001213900-24-020566","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.","Initial invoice of $3.5M due upon execution; $1.5M deposit before dosing; $1.375M per patient for 20 patients.","Estimated dosing: 6 patients by end of 2024, 14 more by end of 2025; study close-out by end of 2025.","Eureka Therapeutics, controlling shareholder of Estrella, provides services; includes cooperation for financing compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249622,"accession_number":"0001213900-24-009325","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Estrella Immunopharma dismisses Marcum as auditor, appoints MGO for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP dismissed as independent auditor effective Jan 30, 2024; no disagreements with Marcum.","Marcum's audit report for FY2023 included a going concern explanatory paragraph.","Macias Gini & O'Connell (MGO) appointed as new auditor for fiscal year ending June 30, 2024.","No consultations with MGO on accounting principles or disagreements prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249621,"accession_number":"0001213900-24-007723","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma authorizes up to $1M share repurchase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $1 million of common stock repurchases; no binding commitment.","Timing, amount and method of repurchases to be determined by market conditions.","CEO and CFO state authorization reflects confidence in Estrella's value and strategic direction.","Repurchase program covers stock traded on Nasdaq under ticker ESLA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267104,"accession_number":"0001213900-23-087115","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K/A","filed_at":"2023-11-14T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"Estrella Immunopharma changes fiscal year to June 30, effective Sept 29, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Fiscal year end changed from December 31 to June 30, effective upon close of business combination.","Change aligns fiscal year with Estrella Biopharma, the accounting acquirer in the combination.","First fiscal year under new end will be the period ending June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267105,"accession_number":"0001013762-23-002216","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["2.01","1.01","2.03","3.02","9.01","3.01","3.03","5.03","5.01","5.02","5.05","5.06"],"status":"ready","headline":"TradeUP Acquisition Corp completes merger with Estrella Biopharma; becomes Estrella Immunopharma, listing on Nasdaq","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration of $325M; Estrella stockholders receive 32.5M shares; name changes to Estrella Immunopharma.","Gross proceeds of ~$23.11M from PIPE ($10M) and Series A sales ($9.75M); funds expected to support operations into 2024.","Officers/directors own ~92.3% of outstanding shares; former UPTD holders own ~4.8%.","Common stock (ESLA) and warrants (ESLAW) start trading on Nasdaq on Oct 2, 2023.","Entered into $50M equity line with White Lion Capital; 3.5M shares authorized under 2023 Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284371,"accession_number":"0001213900-23-077995","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. enters $10M PIPE agreements with price adjustment for Estrella merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two investors commit $5M each at $10/share; additional shares if VWAP < $8.30 at closing or after 24 months.","Pro forma combined equity ~$10.9M as of June 30; estimated to drop to ~$6.2M by Oct 2023 due to burn rate.","Closing conditioned on Business Combination; funds returned if merger doesn't close within 2 business days of expected date.","Company to file resale registration statement; must be effective within 90 days or 10 business days after SEC notice.","Subscription agreements include representations, warranties, and indemnification for Securities Act liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284370,"accession_number":"0001213900-23-077392","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. extends deadline to Oct 19, 2023; Estrella deposits $37,432.70 into trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Monthly extension fee of $37,432.70 ($0.05 per Remaining Share) deposited into trust account to extend deadline from Sept 19 to Oct 19, 2023.","Payment made by Estrella Biopharma pursuant to Merger Agreement dated Sept 30, 2022; evidenced by unsecured, non-interest-bearing promissory note.","Extension Note convertible into common stock of TradeUP at $10.00 per share; repayable if business combination terminates.","Company may extend monthly from July 19, 2023 to July 14, 2024 by depositing Monthly Extension Fee each month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284369,"accession_number":"0001213900-23-069046","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"TradeUP extends business combination deadline to Sept 19 with $37,432.70 deposit from Estrella","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extension fee of $37,432.70 ($0.05 per share) deposited into trust account to extend deadline to September 19, 2023.","Payment made by merger partner Estrella Biopharma under Merger Agreement; recorded as unsecured promissory note.","Note convertible into shares at $10/share if business combination closes; repayable if deal terminates.","Company retains ability to extend monthly through July 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284368,"accession_number":"0001213900-23-061514","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"TradeUP Acquisition stockholders approve merger with Estrella Biopharma; 650K shares redeemed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 1,884,258 for vs 631 against to adopt Merger Agreement with Estrella Biopharma.","All six charter amendment proposals passed, including name change to Estrella Immunopharma, Inc.","Directors appointed: Cheng Liu, Marsha Roberts, Fan Wu, Janelle Wu, Pei Xu.","Estrella Immunopharma 2023 Omnibus Incentive Plan approved, contingent on closing.","650,580 shares of common stock were redeemed in connection with the vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284367,"accession_number":"0001213900-23-059815","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"TradeUP Acquisition enters $6.8M PIPE investment with Suma Ventures for Estrella merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TradeUP (UPTD) signed binding PIPE term sheet with Suma Ventures to acquire $6.8M payables of Estrella prior to merger closing.","At closing, TradeUP will issue 680,000 Class B units (common + preferred) to Suma in exchange for waiving the $6.8M indebtedness.","Preferred stock converts six months after closing at price = max($10 - higher of closing price or 20-day VWAP, floor $4.15).","New Estrella common stock expected to list on Nasdaq under ticker 'ESLA'; all shares subject to one-year lock-up.","Transaction is conditioned on closing of the previously announced business combination between TradeUP and Estrella Biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284366,"accession_number":"0001213900-23-058655","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. issues $50,000 promissory note to founder Tradeup INC.","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Unsecured $50,000 promissory note to founder Tradeup INC. dated July 20, 2023, for working capital.","Non-interest bearing; payable upon business combination or company term expiry, whichever is earlier.","Payee may convert into private shares at $10 per share at least two business days before business combination.","Repayment excludes trust account funds; no claim on trust proceeds if no business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284365,"accession_number":"0001213900-23-058025","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. extends business combination deadline to August 19, 2023 via $37,433 deposit by Estrella","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TradeUP extends deadline to complete initial business combination by one month to August 19, 2023.","Estrella deposited $37,432.70 ($0.05 per remaining share) into trust account for the extension.","Deposit funded by unsecured promissory note from TradeUP to Estrella, convertible into shares at $10.00.","Company may continue monthly extensions up to July 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284364,"accession_number":"0001213900-23-058024","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["1.01","5.03","5.07","8.01","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. extends business combination deadline to July 14, 2024 after stockholder vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved extension of deadline from July 19, 2023 to July 14, 2024 via charter and trust amendment.","161,566 shares of common stock were redeemed in connection with the extension vote.","Monthly deposit of $0.05 per public share into trust account required during extension period.","Re-elected directors Tao Jiang and James as Class II directors for three-year term.","Ratified Marcum LLP as independent auditor for fiscal year ending December 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284363,"accession_number":"0001213900-23-056454","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. to liquidate trust account into cash, announces July 31 special meeting for Estrella merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Trust account to liquidate U.S. treasury obligations and money market funds on July 14, 2023; proceeds held in cash to avoid Investment Company Act classification.","Proxy statement/prospectus for business combination with Estrella Biopharma declared effective July 11, 2023; special meeting set for July 31, 2023.","Extension meeting on July 17, 2023 to vote on extending combination deadline to July 14, 2024; redemption price ~$10.51/share if extension approved.","Public stockholders may redeem shares at ~$10.51 in connection with extension (deadline July 13) or at expected ~$0.05 higher for merger (deadline July 27).","If extension approved, additional $0.05 per share deposited monthly into trust for each non-redeemed share beyond July 19, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304051,"accession_number":"0001575872-23-001032","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TradeUP Acquisition receives Nasdaq extension to Oct 16, 2023 for Public Holder Rule compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted extension until October 16, 2023 to regain compliance with Listing Rule 5550(a)(3).","Company had previously disclosed non-compliance and submitted a compliance plan on June 5, 2023.","Failure to regain compliance by deadline may result in delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304050,"accession_number":"0001575872-23-001000","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. extends business combination deadline to July 19, 2023 with $45,511 deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estrella Biopharma deposited $45,511 into trust to extend deadline from June 19 to July 19, 2023.","Extension Note issued to Estrella, unsecured, non-interest-bearing, convertible into shares at $10.00 per share.","Deposit equals $0.05 per public share for the one-month extension.","Company may continue monthly extensions through July 19, 2023 per its charter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304049,"accession_number":"0001575872-23-000920","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. issues $60K promissory note to founder for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $60,000 unsecured promissory note to Tradeup INC., a founder, on June 6, 2023.","Note bears no interest; principal due upon business combination or company term expiry.","Payee may convert note into private shares at $10.00 per share at least two days before close.","Proceeds used for general working capital until initial business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304048,"accession_number":"0001575872-23-000800","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"TradeUP Acquisition extends business combination deadline to June 19, 2023; Estrella deposits $45,511","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company extended deadline to complete initial business combination from May 19 to June 19, 2023.","Estrella Biopharma deposited $45,511 ($0.05 per public share) into trust account for the extension.","Deposit evidenced by unsecured zero-interest promissory note; convertible into shares at $10.00 per share.","Note payable upon consummation of business combination or within 5 business days of termination.","Extension is pursuant to existing merger agreement with Estrella Biopharma, dated September 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304047,"accession_number":"0001575872-23-000629","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TradeUP Acquisition amends stock purchase agreement; Estrella to issue 250K preferred shares as commitment fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Common Stock Purchase Agreement with White Lion Capital, dated April 26, 2023.","Commitment fee changed: Estrella Biopharma to issue 250,000 Series A preferred shares ($250,000 value) to White Lion immediately prior to merger closing.","Amendment modifies Sections 7.1(v) and 10.1(ii) of the original agreement; all other terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304046,"accession_number":"0001575872-23-000606","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TradeUP Acquisition Corp. enters $50M common stock purchase agreement with White Lion Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $50M in common stock may be sold to White Lion at 97% of VWAP post-business combination with Estrella Biopharma.","Commitment fee of 250,000 shares of Estrella Series A Preferred Stock valued at $250,000 to be issued to White Lion.","Investor may terminate if registration statement lapses for 45 consecutive trading days or other material breaches.","Purchase price adjusts to 98% of VWAP after $25M of shares purchased.","Company must register shares for resale within 30 days of business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304045,"accession_number":"0001575872-23-000592","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TradeUP Acquisition receives Nasdaq deficiency notice for failing minimum public holders rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified TradeUP on April 19, 2023 it fails to meet minimum 300 public holders required by Listing Rule 5550(a)(3).","Company has 45 calendar days to submit a compliance plan; extension of up to 180 days may be granted if plan accepted.","Notice is a deficiency notification, not an immediate delisting; securities continue trading on Nasdaq Capital Market.","If plan is not accepted, Company may appeal to a Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304044,"accession_number":"0001575872-23-000556","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"TradeUP extends business combination deadline to May 19, 2023 with Estrella deposit of $45,511","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estrella Biopharma deposited $45,511 ($0.05 per public share) into trust to extend deadline from April 19 to May 19, 2023.","Extension Note is unsecured, non-interest bearing, payable upon business combination close or termination.","Estrella has right to convert note into private shares at $10.00 per share before closing.","Company may extend monthly through July 19, 2023 per charter by depositing $45,511 each month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304043,"accession_number":"0001575872-23-000519","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TradeUP Acquisition Corp. receives Nasdaq delisting notice for MVLS below $35M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified TradeUP on April 3, 2023 that its Market Value of Listed Securities (MVLS) was below $35M for 30 consecutive business days.","The deficiency is under Nasdaq Listing Rule 5550(b)(2); the notice does not trigger immediate delisting.","Company has 180 days, until October 2, 2023, to regain compliance by achieving MVLS of at least $35M for 10 consecutive business days.","Failure to cure by the deadline will result in a delisting notice; the company may appeal any such determination.","TradeUP is evaluating options to regain compliance, but there is no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-05T23:59:59+00:00|304043"}